Emerging ADC Designs Provide Opportunity for Differentiated Next Generation ADCs
- The large number of ADCs with tubulin or topoisomerase 1 inhibitor payloads presents a high risk for clinical development of ADCs with these payloads in the future due to overlapping resistance and toxicity
- New payloads with differentiated MOAs will be essential for ADC sequencing in treatment paradigms for patients
- Innovations in linkers and bioconjugation will contribute to reducing the inherent risk in using these new payloads